How often should a male patient over 50 years old with average risk factors for prostate cancer (Prostate Specific Antigen) PSA check his PSA levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

PSA Screening Frequency for Men Over 50

For average-risk men over 50, check PSA every 1-2 years, with the option to extend to every 2-4 years if PSA remains below 1.0 ng/mL. 1

Initial Screening Strategy

The National Comprehensive Cancer Network uniformly recommends baseline PSA testing for healthy, well-informed men aged 50-70 years with at least 10 years life expectancy. 2 This recommendation is supported by the strongest randomized trial evidence showing approximately 1.3 fewer prostate cancer deaths per 1,000 men screened over 13 years. 1, 3

Risk-Stratified Screening Intervals

The frequency of PSA testing should be determined by your initial PSA result rather than using fixed annual intervals for everyone:

For PSA ≥1.0 ng/mL:

  • Repeat testing every 1-2 years 2, 1
  • This interval balances cancer detection with reduced overdiagnosis compared to annual screening 2
  • Screening every 2 years reduces advanced prostate cancer diagnosis by 43% compared to every 4 years, though it does increase low-risk cancer detection by 46% 1

For PSA <1.0 ng/mL:

  • Repeat testing every 2-4 years 1, 4
  • Men aged 60 with PSA <1.0 ng/mL have only 0.5% risk of metastases and 0.2% risk of prostate cancer death, supporting longer screening intervals 1, 4

Evidence Supporting Biennial Screening

Microsimulation models demonstrate that biennial screening in men with average PSA levels provides comparable survival to annual screening while achieving: 2

  • 59% reduction in total tests
  • 50% reduction in false-positive results
  • Lower overdiagnosis rate (2.4% vs 3.3% for annual screening)

The European Randomized Study of Screening for Prostate Cancer (ERSPC) trial directly compared screening intervals, showing that 2-year intervals significantly reduced advanced cancer diagnoses compared to 4-year intervals. 2

When to Stop Screening

Discontinue routine PSA screening at age 70 in most men. 1, 4 Continue beyond age 70 only in very healthy men with minimal comorbidity, prior elevated PSA values, and life expectancy >10-15 years. 1, 4 The USPSTF recommends against PSA screening in men 70 years and older, as potential benefits do not outweigh expected harms. 1, 3

Men aged 75 years or older with PSA <3.0 ng/mL are unlikely to die from prostate cancer and may safely discontinue screening. 2, 1

Critical Monitoring Triggers

Regardless of your routine screening interval, consider prostate biopsy if PSA increases by ≥1.0 ng/mL in any 12-month period, regardless of absolute PSA value. 4, 5 If PSA rises by 0.7-0.9 ng/mL in one year, repeat measurement in 3-6 months and perform biopsy if there is any further increase. 4

Common Pitfalls to Avoid

  • Don't use fixed annual screening for all men – this leads to unnecessary testing and false-positives in low-risk individuals 1
  • Don't test within 48 hours of ejaculation – this causes false-positive elevations 5
  • Don't act on a single elevated PSA – 40-44% of initially elevated values normalize on repeat testing 5
  • Don't continue screening in men with limited life expectancy – screening men with <10 years life expectancy provides no benefit and only causes harm 1

References

Guideline

Age Recommendations for PSA Screening Initiation in Prostate Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Elevated PSA

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Factors Affecting PSA Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.